Conversely, proteasome activation can be beneficial in treating neurodegenerative and heart diseases, which can be achieved by kinase activators (as in the case of PKA and PKG) or phosphatase inhibitors (as in the case of UBLCP1). This evidence concerns the gene PRKG1 and heart disorder.